Trial Profile
A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Cardiovascular disorders; Glucose intolerance; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ORIGIN; ORIGIN-GRACE; ORIGINALE
- Sponsors Sanofi
- 28 Aug 2023 Results of biomarker substudy within the ORIGIN (n=8,494) assessing the relationship between SHBG levels and heart failure hospitalizations in men and women with dysglycemia presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 01 Mar 2023 Results(n=7017) Identifying blood biomarkers for type 2 diabetes subtyping using up to six routinely measured clinical variables published in the Diabetologia
- 01 Mar 2022 Results of a pooled analysis of six-month efficacy data of iGlarLixi and Standard of Care (SOC) were extracted from the LixiLan-O (NCT02058147) and ORIGIN (NCT00069784) trials assessing the efficacy of iGlarLixi published in the Journal of Diabetes and its Complications